Heska Corporation (Nasdaq: HSKA – news) today announced that Ralston Purina Company has introduced the first nutritional product to result from the Ralston Purina-Heska alliance. CNM® brand DM-Formula(TM) is a revolutionary new diet available only through veterinarians for the nutritional management of feline diabetes mellitus. Ralston Purina, who will market this product, formally introduced it to the market place at the American Veterinary Medical Association annual meeting, which was recently held in Salt Lake City.
Robert Grieve, Chairman and Chief Executive Officer of Heska, said, “In addition to the importance of introducing a diet which should have a positive impact on the management of feline diabetes, it is particularly satisfying to see the first product result from this important alliance. When this strategic alliance was announced two years ago it was the result of a vision that paired the deep understanding of companion animal food nutrition of the world’s largest manufacturer of dry dog food and dry and soft-moist cat foods with a company focused on bringing product innovations to companion animal health. The creation and market introduction of CNM DM-Formula is a validation of that vision and underscores the future potential in this alliance. We are hopeful that this is the first in a series of many novel new nutritional products that will result from our collaborative efforts with Ralston Purina.”
Heska discovers, develops, manufactures and markets companion animal health products, primarily for dogs, cats and horses. Heska has a sophisticated scientific effort devoted to applying biotechnology to the large and growing companion animal health market. Heska also offers diagnostic and patient monitoring instrumentation and supplies, as well as laboratory diagnostic products in the United States and Europe to veterinarians, and operates a USDA- and FDA-licensed facility, which manufactures vaccines and pharmaceutical products. For additional information on Heska and its products, visit the company’s web site at www.heska.com.
With the exception of historical matters, this press release contains express or implied forward-looking information about Heska’s technology, potential future products, potential licenses or collaborative agreements, including statements concerning the ability to create new products utilizing these technologies or enter into collaborations with partners for human applications. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of Heska to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Heska’s achievement of these results may be affected by many factors, including among others, the following: uncertainties whether this technology will be licensed, uncertainties regarding the outcome of research and development efforts or the ability to successfully develop or commercialize products in research and development, uncertainties with respect to entering into collaborations with partners to develop the technology, uncertainties regarding the ability to receive required regulatory approvals in a timely manner, if at all, uncertainties regarding the scope, enforceability and validity of patents and proprietary rights, which are subject to complex legal standards that vary from country to country and are subject to interpretation by administrative agencies and courts, quality of management, competition, changes in business strategy or development plans, inability to manufacture, market, sell or distribute products described herein, inability to manufacture, market, sell or distribute products at currently projected costs and the risks set forth in Heska’s filings and future filings with the Securities and Exchange Commission, including those set forth in Heska’s Annual Report on Form 10-K for the year ended December 31, 1999 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2000.